This is the authors' abstract. We don't add key points for this paper.
Our results suggest that trastuzumab modulates the systemic inflammatory conditions and overcomes the poor prognostic impact of high NLR/MLR. This finding may also provide a rationale for combining trastuzumab with immuno-oncological treatments in HER2+ breast cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tiainen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: